Characterization of phosphodiesterase Type 5 expression and functional activity in the human male lower urinary tract

Journal of Sexual Medicine

Volumn 7, Issue 1 PART 1, 2010, Pages 59-69

  Fibbi, Benedetta ^a   Morelli, Annamaria ^a   Vignozzi, Linda ^a   Filippi, Sandra ^a   Chavalmane, Aravinda ^a   De Vita, Giulia ^a   Marini, Mirca ^a   Gacci, Mauro ^a   Vannelli, Gabriella Barbara ^a   Sandner, Peter ^b   Maggi, Mario ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b BAYER PHARMA AG   (Germany)

Author keywords

Human smooth muscle cell proliferation; Lower urinary tract; Lower urinary tract symptoms; Phosphodiesterase type 5

Indexed keywords

2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL] 5 MORPHOLINO 4,6 PYRIMIDINEDIAMINE; CYCLIC GMP; CYCLIC GMP DERIVATIVE; MESSENGER RNA; NITRIC OXIDE; NITROPRUSSIDE SODIUM; PHOSPHODIESTERASE V; VARDENAFIL;

AGED; ARTICLE; BLADDER; CELL PROLIFERATION; CONTROLLED STUDY; DRUG ACTIVITY; ENZYME ACTIVITY; ENZYME LOCALIZATION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROSTATE; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SMOOTH MUSCLE FIBER; TISSUE DISTRIBUTION; URETHRA;

EID: 74049146047     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2009.01511.x     Document Type: Article

References (39)

1. Sairam K, Kulinskaya E, McNicholas TA, Boustead GB, Hanbury DC. Sildenafil influences lower urinary tract symptoms. BJU Int 2002, 90:836-9.
2. Mulhall JP, Guhring P, Parker M, Hopps C. Assessment of the impact of sildenafil citrate on lower urinary tract symptoms in men with erectile dysfunction. J Sex Med 2006, 3:662-7.
3. McVary KT, Roehrborn CG, Kaminetsky JC, Auerbach SM, Wachs B, Young JM, Esler A, Sides GD, Denes BS. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 2007, 177:1401-7.
4. Porst H, McVary KT, Montorsi F, Sutherland P, Elion-Mboussa A, Wolka AM, Viktrup L. Effects of once-daily tadalafil on erectile function in men with erectile dysfunction and signs and symptoms of benign prostatic hyperplasia. Eur Urol 2009, Epub ahead of print
5. McVary KT, Kaufman J, Young JM, Tseng LJ. Sildenafil citrate improves erectile function: A randomised double-blind trial with open-label extension. Int J Clin Pract 2007, 61:1843-9.
6. McVary KT, Siegel RL, Carlsson M. Sildenafil citrate improves erectile function and lower urinary tract symptoms independent of baseline body mass index or LUTS severity. Urology 2008, 72:575-9.
7. Stief CG, Porst H, Neuser D, Beneke M, Ulbrich E. A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol 2008, 53:1236-44.
8. Gacci M, Del Popolo G, Macchiarella A, Celso M, Vittori G, Lapini A, Serni S, Sandner P, Maggi M, Carini M. Vardenafil improves urodynamic parameters in men with spinal cord injury: Results from a single dose, pilot study. J Urol 2007, 178:2040-3.
9. Gacci M, Maggi M, Carini M. Re: Christian G. Stief, Hartmut Porst, Dieter Neuser, et al. A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol 2008, 53:1236-44. Eur Urol 2008 [Epub ahead of print]
10. Filippi S, Morelli A, Sandner P, Fibbi B, Mancina R, Marini M, Gacci M, Vignozzi L, Vannelli GB, Carini M, Forti G, Maggi M. Characterization and functional role of androgen-dependent PDE5 activity in the bladder. Endocrinology 2007, 148:1019-29.
11. Morelli A, Filippi S, Sandner P, Fibbi B, Chavalmane AK, Silvestrini E, Sarchielli E, Vignozzi L, Gacci M, Carini M, Vannelli GB, Maggi M. Vardenafil modulates bladder contractility through cGMP-mediated inhibition of rhoa/rho kinase signaling pathway in spontaneously hypertensive rats. J Sex Med 2009, 6:1594-608.
12. Gacci M, Ierardi A, Delle Rose A, Tazzioli S, Scapaticci E, Filippi S, Maggi M, Nicita G, Carini M, Montorsi F. Vardenafil can improbe continence recovery after bilateral nerve sparing prostatectomy: Results of a randomized, double blind, placebo controlled pilot study. J Sex Med 2009, in press
13. Kedia GT, Uckert S, Jonas U, Kuczyk MA, Burchardt M. The nitric oxide pathway in the human prostate: Clinical implications in men with lower urinary tract symptoms. World J Urol 2008, 26:603-9.
14. Burnett AL, Maguire MP, Chamness SL, Ricker DD, Takeda M, Lepor H, Chang TS. Characterization and localization of nitric oxide synthase in the human prostate. Urology 1995, 45:435-9.
15. Bloch W, Klotz T, Loch C, Schmidt G, Engelmann U, Addicks K. Distribution of nitric oxide synthase implies a regulation of circulation, smooth muscle tone, and secretory function in the human prostate by nitric oxide. Prostate 1997, 33:1-8.
16. Dixon JS, Jen PY. Development of nerves containing nitric oxide synthase in the human male urogenital organs. Br J Urol 1995, 76:719-25.
17. Waldkirch ES, Uckert S, Langnäse K, Richter K, Jonas U, Wolf G, Andersson KE, Stief CG, Hedlund P. Immunohistochemical distribution of cyclic GMP-dependent protein kinase-1 in human prostate tissue. Eur Urol 2007, 52:495-501.
18. Takeda M, Tang R, Shapiro E, Burnett AL, Lepor H. Effects of nitric oxide on human and canine prostates. Urology 1995, 45:440-6.
19. Andersson KE, Uckert S, Stief C, Hedlund P. Phosphodiesterases (PDEs) and PDE inhibitors for treatment of LUTS. Neurourol Urodyn 2007, 26:928-33.
20. Tinel H, Stelte-Ludwig B, Hutter J, Sandner P. Pre-clinical evidence for the use of phosphodiesterase-5 inhibitors for treating benign prostatic hyperplasia and lower urinary tract symptoms. BJU Int 2006, 98:1259-63.
21. Guh JH, Hwang TL, Ko FN, Chueh SC, Lai MK, Teng CM. Antiproliferative effect in human prostatic smooth muscle cells by nitric oxide donor. Mol Pharmacol 1998, 53:467-74.
22. Cook AL, Haynes JM. Protein kinase G II-mediated proliferative effects in human cultured prostatic stromal cells. Cell Signal 2004, 16:253-61.
23. Uckert S, Kuthe A, Jonas U, Stief CG. Characterization and functional relevance of cyclic nucleotide phosphodiesterase isoenzymes of the human prostate. J Urol 2001, 166:2484-90.
24. Uckert S, Oelke M, Stief CG, Andersson KE, Jonas U, Hedlund P. Immunohistochemical distribution of cAMP- and cGMP-phosphodiesterase (PDE) isoenzymes in the human prostate. Eur Urol 2006, 49:740-5.
25. Morelli A, Filippi S, Mancina R, Luconi M, Vignozzi L, Marini M, Orlando C, Vannelli GB, Aversa A, Natali A, Forti G, Giorni M, Janni EA, Ledda F, Maggi M. Androgens regulate phosphodiesterase type 5 expression and functional activity in corpora cavernosa. Endocrinology 2004, 145:2253-63.
26. Werkstrom V, Svensson A, Andersson KE, Hedlund P. Phosphodiesterase 5 in the female pig and human urethra: Morphological and functional aspects. BJU Int 2009, 98:414-23.
27. Hedlund P, Ekstrom P, Larsson B, Alm P, Andersson KE. Heme oxygenase and NO-synthase in the human prostate-relation to adrenergic, cholinergic and peptide-containing nerves. J Auton Nerv Syst 1997, 63:115-26.
28. Uckert S, Sormes M, Kedia G, Scheller F, Knapp WH, Jonas U, Stief CG. Effects of phosphodiesterase inhibitors on tension induced by norepinephrine and accumulation of cyclic nucleotides in isolated human prostatic tissue. Urology 2008, 71:526-30.
29. Crescioli C, Maggi M, Vannelli GB, Luconi M, Salerno R, Barni T, Gulisano M, Forti G, Serio M. Effect of a vitamin D3 analogue on keratinocyte growth factor-induced cell proliferation in benign prostate hyperplasia. J Clin Endocrinol Metab 2000, 85:2576-83.
30. D'Amati G, di Gioia CR, Bologna M, Giordano D, Giorgi M, Dolci S, Jannini EA. Type 5 phosphodiesterase expression in the human vagina. Urology 2002, 60:191-5.
31. Stasch JP, Alonso-Alija C, Apeler H, Dembowsky K, Feurer A, Minuth T, Perzborn E, Schramm M, Straub A. Pharmacological actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: In vitro studies. Br J Pharmacol 2002, 135:333-43.
32. De Lean A, Munson PJ, Rodbard D. Simultaneous analysis of families of sigmoidal curves: Applications to biossay, radioligand assay, and physiological dose-response curves. Am J Physiol 1978, 235:E97-102.
33. Oger S, Behr-Roussel D, Gorny D, Lecoz O, Lebret T, Denoux Y, Faix A, Leriche A, Wayman C, Alexandre L, Giuliano G. Combination of doxazosine and sildenafil exerts an additive relaxing effect compared with each compound alone on human cavernosal and prostatic tissue. J Sex Med 2009, 6:836-47.
34. Kang KK, Kin JM, Yu JY, Ahn BO, Kin YC. Effects of phosphodiesterase type 5 inhibitor on the contractility of prostate tissues and urethral pressure responses in a rat model of benign prostatic hyperplasia. Int J Urol 2007, 14:946-51.
35. Oger S, Behr-Roussel D, Gorny D, Lebret T, Denoux Y, Alexandre L, Giuliano F. Combination of alfuzosin and tadalafil exerts an additive relaxant effect on human detrusor and prostatic tissues in vitro. Eur Urol 2009, May 3 [Epub ahead of print] doi: 10.1016/j.eururo.2009.04.039
36. Gupta M, Kovar A, Meibohm B. The clinical pharmacokinetics of phosphodiesterase-5 inhibitors for erectile dysfunction. J Clin Pharmacol 2005, 45:987-1003.
37. Saenz de Tejada I, Angulo J, Cuevas P, Fernández A, Moncada I, Allona A, Lledó E, Körschen HG, Niewöhner U, Haning H, Pages E, Bischoff E. The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil. Int J Impot Res 2001, 13:282-90.
38. Bischoff E. Potency, selectivity, and consequences of nonselectivity of PDE inhibition. Int J Impot Res 2004, 16:S11-4.
39. Datta SN, Kavia RB, Gonzales G, Fowler CJ. Results of double-blind placebo-controlled crossover study of sildenafil citrate (Viagra) in women suffering from obstructed voiding or retention associated with the primary disorder of sphincter relaxation (Fowler's Syndrome). Eur Urol 2007, 51:489-95.